The adipokine vaspin is associated with decreased coronary in-stent restenosis in vivo and inhibits migration of human coronary smooth muscle cells in vitro

Stefan P. Kastl\textsuperscript{1,2}, Katharina M. Katsaros\textsuperscript{1,2}, Konstantin A. Krychtiuk\textsuperscript{1,2}, Gerlinde Jägersberger\textsuperscript{1}, Christoph Kaun\textsuperscript{1}, Kurt Huber\textsuperscript{3}, Johann Wojta\textsuperscript{1,2,}*, Walter S. Speidl\textsuperscript{1}

1 Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria, 2 The Ludwig Boltzmann Cluster for Cardiovascular Research, Vienna, Austria, 3 Department of Medicine (Cardiology and Emergency Medicine), Wilhelminenspital, Vienna, Austria

* johann.wojta@meduniwien.ac.at

Abstract

Background
Percutaneous coronary intervention represents the most important treatment modality of coronary artery stenosis. In-stent restenosis (ISR) is still a limitation for the long-term outcome despite the introduction of drug eluting stents. It has been shown that adipokines directly influence vessel wall homeostasis by influencing the function of endothelial cells and arterial smooth muscle cells. Visceral adipose tissue-derived serpin vaspin was recently identified as a member of serine protease inhibitor family and serveral studies could demonstrate a relation to metabolic diseases. The aim of this study was to investigate a role of vaspin in the development of in-stent restenosis in vivo and on migration of smooth muscle cells and endothelial cells in vitro.

Methods
We studied 85 patients with stable coronary artery disease who underwent elective and successful PCI with implantation of drug eluting stents. Blood samples were taken directly before PCI. Vasin plasma levels were measured by specific ELISA. ISR was evaluated eight months later by coronary angiography. Human coronary artery smooth muscle cells (HCASMC) and human umbilical vein endothelial cells (HUVEC) migration was analyzed by an in-vitro migration assay with different concentrations (0.004ng/mL up to 40ng/mL) of vaspin as well as by an scratch assay. For proliferation an impedance measurement with specialized E-Plates was performed.

Results
During the follow up period, 14 patients developed ISR. Patients with ISR had significantly lower vaspin plasma levels compared to patients without ISR (0.213 ng/ml vs 0.382 ng/ml; p
In patients with plasma vaspin levels above 1.35 ng/ml we could not observe any restenosis. There was also a significant correlation of plasma vaspin levels and late lumen loss in the stented coronary segments. Further we could demonstrate that vaspin nearly abolishes serum induced migration of HCASMC (100% vs. 9%; p<0.001) in a biphasic manner but not migration of HUVEC. Proliferation of HCASMC and HUVEC was not modulated by vaspin treatment.

Conclusion
We were able to show that the adipokine vaspin selectively inhibits human coronary SMC migration in vitro and has no effect on HUVEC migration. Vaspin had no effect on proliferation of HUVEC which is an important process of the healing of the stented vessel. In addition, the occurrence of ISR after PCI with implantation of drug eluting stents was significantly associated with low vaspin plasma levels before intervention. Determination of vaspin plasma levels before PCI might be helpful in the identification of patients with high risk for development of ISR after stent implantation. In addition, the selective effects of vaspin on smooth muscle cell migration could potentially be used to reduce ISR without inhibition of re-endothelialization of the stented segment.

Introduction
Percutaneous coronary intervention (PCI) represents the most important treatment modality of coronary artery stenosis. However the occurrence of In-stent restenosis (ISR) is still a limitation for the long-term outcome despite the introduction of drug eluting stents (DES).[1] Several contributory factors have been identified during the last years, but the overall underlying mechanisms are still unclear.

ISR occurs at different points in time (early and late restenosis) after implantation of a DES and involves numerous cellular and molecular mechanisms. [2,3] The pathophysiology of restenosis involves accumulation of new tissue within the arterial wall. Smooth muscle cell (SMC) migration and extracellular matrix secretion (ECM) plays a central role in neointimal hyperplasia (NIH), which is nowadays seen as pathognomonic of ISR.[4] ECM synthesis by these SMCs is responsible for the increasing volume of intimal tissue, which is composed of ECM proteoglycans and collagens.[5] Over the months after the implantation of a DES there is a shift towards greater ECM synthesis rather than SMC proliferative activity.[6,7] So inhibition of initial SMC migration to the media could play a key role in later NIH. But unlike the proliferative aspect of the SMCs, little is known about their “motile” activity after stent-implantation, which allows them to migrate into the media. The use of DES reduced the incidence of restenosis but the cytostatic agents also delayed endothelialization of the implanted stent which plays a key role for the long-term outcome. Incomplete endothelialization can lead to stent-thrombosis and acute myocardial infarction after stopping of antiplatelet therapy.

Vaspin is an adipocytokine that has been isolated from the visceral adipose tissue of Otsuka Long-Evans Tokushima Fatty (OLETF) rats, which is a diabetes rat model.[8] Due to the fact that vaspin is characterized by the presence of a core domain consisting of three β-sheets and nine α-helices it is likely that vaspin belongs to the serine protease inhibitors (serpin) family.[9,10] But still nothing is known about the physiologic inhibitory function of vaspin. Several Studies in OLETF could demonstrate that vaspin production decreased as diabetes worsened
but increased by treatment with insulin or pioglitazone.[11] This suggests that the up-regulation of vaspin may have a defensive action against insulin resistance. A recent study could clearly show that vaspin is also produced by periadventitial adipose tissue which may play an important paracrine role during the development of ISR.[12]

Therefore we tested whether plasma levels of vaspin are related to the clinical manifestation of ISR in patient with stable coronary artery disease that have received an DES and if vaspin inhibits the migration of smooth muscle cells and endothelial cells in vitro. Further, we wanted to know if vaspin has any negative effects on the healing process (endothelialization) of the stented vessel.

Methods
Patients
Blood samples were taken prospectively from all patients with stable coronary artery disease who were scheduled for elective PCI. The type, number, length, and size of the stent(s) implanted were left to the discretion of the interventionalist. All patients with DES only (n = 107) were asked to participate in this study, and we included all 85 patients who gave their informed consent for follow-up angiography.

Paclitaxel-eluting stents (Taxus; Boston Scientific, Boston, MA, USA) were implanted in 62 patients (72.9%); sirolimus-eluting stents (Cypher; Cordis, Johnson & Johnson, Miami Lakes, FL, USA) were used in 23 patients (27.1%). The study was approved by the institutional ethics committee (Ethikkommission der Medizinischen Universität Wien). Patients with concurrent severe illness, acute coronary syndrome within three months before angioplasty, PCI for restenosis and unsuccessful procedure were excluded. Clopidogrel therapy was either started on the day before angiography (n = 56) or immediately after stent implantation (n = 29) with four tablets (300 mg). During the intervention, all patients were treated with unfractionated heparin. After the procedure, patients were maintained on 100 mg aspirin indefinitely, 75 mg clopidogrel for at least 6 months. Other medications were given in accordance with the relevant guidelines and regulations.

Angiographic definitions
Quantitative coronary angiographic analysis was performed by a single, experienced researcher who was blinded to clinical characteristics and laboratory measurements. The modified American College of Cardiology/American Heart Association grading system (types A, B1, B2, and C) was used to characterize lesion morphology. The off-line quantitative coronary angiographic analysis was performed with an automated edge-detection system (QCA-CMS V 6.0; Medis, Medical Imaging Systems). A contrast-filled nontapered catheter tip was used for calibration. The reference diameter was measured by interpolation. The angiographic parameters that have been measured were vessel size maximal balloon pressure (atm), balloon-to-vessel ratio, lesion length, and length of stented segment. Minimal luminal diameter (prior and post procedure) and diameter stenosis (prior and post procedure) have been measured in-stent and in-segment (including the stented segment, as well as both 5mm margins proximal and distal to the stent). Angiographic restenosis was evaluated at six to eight months follow-up, or earlier if clinically indicated. The primary end point of the study was angiographic restenosis (diameter stenosis of at least 50% based on in-segment analysis) at follow-up angiography. The secondary end points were in-stent LL and the need for target lesion revascularization due to restenosis in the presence of symptoms or objective signs of ischemia during follow-up.
Blood sampling

After informed consent was obtained, blood samples were taken under fasting conditions. Samples were taken in the morning before PCI (before treatment with unfractionated heparin). Therefore, venous blood was drawn from the antecubital vein with minimal tourniquet pressure into EDTA tubes. After centrifugation (4°C; 660g for 25 min) plasma samples were stored at -80°C until use.

Cell culture experiments

Human coronary artery smooth muscle cells (HCASMC) were isolated from pieces of coronary arteries obtained from patients undergoing heart transplantation. Such smooth muscle cells were cultured and characterized as already described.[13] Human umbilical vein endothelial cells (HUVEC) were isolated from fresh umbilical cords by mild collagenase treatment, and cultivated as described.[14]

Cell migration assay

The migration of HCASMC and HUVEC was examined using a colorimetric cell migration assay (Millipore, Billerica, USA) based on the Boyden chamber principle using inserts with a pore size of 8 μm.

HCASMC and HUVEC were trypsinized, washed 2x with PBS, resuspended in 1% FBS in M199 in the presence or absence of vaspin of different concentrations (0.004ng/mL up to 4ng/mL), and afterwards added to the upper tray (2.5x10^5 cells/300μL). M199 with 10% FBS and the same concentration of vaspin as in the upper tray was added to the bottom chamber. As a negative control we used serum free M199 in both chambers. After 6 hours at 37°C, nonmigrating cells were scraped from the upper surface of the filter. Cells on the bottom surface were incubated with Cell Stain Solution (Millipore, Billerica, USA), then subsequently extracted and detected by spectrophotometry (absorbance at 560 nm).

Scratch assay

HCASMC and HUVEC were trypsinized, washed 2x with PBS and resuspended in 1% FBS in M199. Cells were seeded into 6-well plates at a concentratrion of 5x10^5 cells / well. After 24h the cell monolayer was "scratched" in a straight line with a 200μL pipet tip. The debris of the scratch was removed by washing the cells once with growth medium and then cells were ether stimulated with 4ng/ml vaspin or PBS as a control. After 24h remigration into the the scratched area was analyzed under the microscope. Each experiment was repeated 3 times and a representative sample is shown.

Measurement of proliferation

Cells (HUVECs and HCASMCs) were seeded at a concentration of 2000 cells/well in the wells of an electronic microtiter plate (E-Plate®) of the xCELLigence System (ACEA Biosciences Inc., San Diego, USA). After 4h of adhesion non-adherent cells were washed away with PBS and vaspin was added at the indicated concentrations. Adhesion of cells to the gold microelectrodes impedes the flow of electric current between electrodes. This impedance value increases as cells proliferate. After 24h differences in impedance were measured.

Determination of vaspin plasma levels

Vaspin antigen was determined by a specific enzyme-linked immunosorbent assays (ELISA), (AdipoGene, Incheon, Korea). (Sensitivity 12 pg/ml)
Statistical analysis

Sample size calculation was based on the hypothesis that vaspin plasma levels show a difference of at least 50% in patients with and without ISR. Calculation of sample size revealed that, with an expected "real world" restenosis rate of 10%, 80 patients were needed to detect a 50% difference in vaspin levels between patients with and without ISR with a power of 80% and significance level (2-tailed) of 0.05 (15). In patients with multiple lesion interventions, only the lesion with the highest late lumen loss was included. Continuous variables are expressed as mean ± SD. Demographic data of patients with and without restenosis were compared by the unpaired Student t test. Categorical variables are summarized as counts and percentages and were compared by the chi-square or by Fisher exact test. Plasma levels of vaspin were compared by Mann-Whitney U test. Spearman's correlation was used to correlate vaspin levels with late lumen loss. Multivariate analysis was performed with the logistic regression model in which restenosis was used as dependent variable and vaspin levels as well as potentially confounding baseline variables were used as independent variables. Baseline variables were selected for the model if they appeared to be imbalanced between patients with and without restenosis indicated by a p-value < 0.20. HCASMC and HUVEC migration and proliferation was analyzed by ANOVA. A value of p < 0.05 (2-tailed) was considered statistically significant. All statistical analyses were performed with the statistical software package SPSS version 11.0 (SPSS, Inc., Chicago, Illinois). The authors had full access to the data and take responsibility for its integrity. All authors have read and agree to the manuscript as written.

Results

Association of vaspin plasma levels with instent-restenosis

Baseline characteristics of study population are given in Table 1. The mean age was 64±10 years and 77.6% of patients were male. In-stent restenosis occurred in 14 (16.5%) patients. Angiographical and interventional characteristics of patients are given in Table 2. Patients with ISR at follow-up angiography had significantly lower vaspin plasma levels before stent-implantation compared to patients without ISR (0.213 ng/ml vs 0.382 ng/ml; p = 0.001; Fig 1A). By dividing plasma vaspin levels into tertiles we could show that the restenosis rate is also strongly related to levels of vaspin (Fig 1B). In patients with plasma vaspin levels in the third tertile before intervention we could not observe any restenosis (0%; p < 0.05). Multivariate regression analysis (Table 3) revealed that a decrease of vaspin plasma levels was associated with ISR independent from clinical variables (hypertension, BMI) and procedural variables (number, diameter and type of stents). By investigating late lumen loss in the stented coronary segment we found a significant correlation with the plasma vaspin levels before intervention (R = 0.3, p < 0.05; Fig 2).

Effect of vaspin on migration of human coronary smooth muscle cells (HCASMC)

Treatment of HCASMC with vaspin decreased migration towards serum in a dose-dependent manner with a maximum inhibitory effect at 4 ng/mL (100±9.26% vs. 9±5.96%; p < 0.001). Interestingly, the inhibitory effect of vaspin was decreased at the higher dose of 40 ng/mL resulting in a U-shaped curve (Fig 3A). In addition, vaspin (4 ng/mL) completely abolished repopulation with HCASMC in a scratch assay (Fig 3C).
Table 1. Baseline characteristics of patients with and without restenosis.

|                         | Total       | Restenosis | No restenosis | p-Value |
|-------------------------|-------------|------------|---------------|---------|
| Age (years)             | 64±10       | 66±7       | 63±10         | 0.32    |
| Sex (male)              | 66 (79)     | 9 (75)     | 57 (80)       | 0.7     |
| Hypertension            | 63 (76)     | 7 (58)     | 56 (78)       | 0.12    |
| Diabetes                | 25 (30)     | 3 (25)     | 22 (31)       | 0.48    |
| Family History of CHD   | 46 (55)     | 7 (58)     | 39 (54)       | 0.54    |
| BMI (kg/m²)             | 27.9±3.7    | 26.6±3.6   | 28.1±3.7      | 0.19    |
| Triglycerides (mg/dl)   | 175±99      | 159±70     | 177±103       | 0.55    |
| TC (mg/dl)              | 189±43      | 186±27     | 190±45        | 0.81    |
| HbA1c                   | 6.02±0.74   | 6.07±0.63  | 6.06±0.77     | 0.83    |
| Leukocytes              | 6.69±1.51   | 6.49±1.83  | 6.73±1.46     | 0.6     |
| ACE-Inhibitors          | 35 (42)     | 7 (58)     | 28 (39)       | 0.34    |
| ARB                     | 10 (12)     | 1 (8)      | 9 (13)        | 1.0     |
| Beta Blocker            | 44 (53)     | 8 (67)     | 36 (51)       | 0.36    |
| Statin                  | 64 (77)     | 9 (75)     | 55 (77)       | 1.0     |

Values are given as mean ± SD or n (%).

ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker; BMI = body mass index; CRP = C-reactive protein; HbA1c = glycosylated hemoglobin; TC = total cholesterol.

https://doi.org/10.1371/journal.pone.0232483.t001

Table 2. Angiographic and procedural characteristics of patients with and without restenosis.

| Angiography Target vessel | Restenosis | No restenosis | p-Value |
|----------------------------|------------|---------------|---------|
|                            | n = 14     | n = 71        |         |
| LAD                        | 8 (57)     | 40 (56.3)     | 0.69    |
| LCx                        | 1 (7)      | 13 (18.3)     |         |
| RCA                        | 5 (36)     | 18 (25.4)     |         |
| Lesion Type (A/B/C)        | 2/10/2     | 17/45/7       | 0.42    |
| Vessel Size                | 3.23±0.39  | 3.26±0.37     | 0.79    |
| MLD (mm)                   | 0.68±0.21  | 0.67±0.23     | 0.99    |
| DS (%)                     | 78.70±7.05 | 80.03±7.14    | 0.55    |
| Number of stents per procedure | 2.33±1.37 | 1.78±0.92 | 0.08 |
| Number of stents per vessel | 1.58±0.79 | 1.30±0.57 | 0.13 |
| Type of Stent              |            |               |         |
| Taxus                      | 13 (93%)   | 48 (69)       | 0.16    |
| Cypher                     | 1 (7%)     | 22 (31)       |         |
| Length of stented segment (mm) | 22.41±0.41 | 20.79±6.40 | 0.4 |
| MLD after procedure        |            |               |         |
| In-stent (mm)              | 2.64±0.41  | 2.68±0.36     | 0.74    |
| In-segment (mm)            | 2.63±0.41  | 2.66±0.35     | 0.78    |

LAD = left anterior descending coronary artery; LCx = left circumflex coronary artery; MLD = minimal lumen diameter; RCA = right coronary artery. MLD = minimal lumen diameter.

https://doi.org/10.1371/journal.pone.0232483.t002
Effect of vaspin on migration of human umbilical vein endothelial cells (HUVEC)

Treatment of HUVEC with the same concentrations of vaspin was not effective in decreasing migration towards serum. It was not possible to demonstrate any effect of inhibition of migration of HUVEC at all. (100±5.65% vs. 98±7.67%; p > 0.05) (Fig 3B). Also, vaspin (4 ng/mL) did not abolish repopulation with HUVEC in a scratch assay (Fig 3D).

Effect of vaspin on the proliferation of HUVEC and HCASMC

Treatment of HUVEC and HCASMC with vaspin at a concentration of 4ng/ml for 24h had no significant effect on the proliferation of these cells compared to cells which were treated with 0ng/ml (HUVEC: 100±11% vs 103±9% p > 0.05; HCASMC: 100±10% vs 101±8.6% p > 0.05). (Fig 4)

Discussion

Locally produced adipokines, especially by periadventitial adipose tissue, may affect vascular physiology and pathology.[12] It has already been described a correlation of vaspin plasma levels with carotid intima-media thickness independent of insulin resistance.[15] This indicates

Table 3. Logistic regression model assessing the risk for in-stent restenosis after implantation of drug-eluting stents according a decrease of plasma levels of vaspin.

|                   | Hazard ratio for 1 SD decrease of vaspin plasma levels | 95% Confidence interval | p-value |
|-------------------|-------------------------------------------------------|-------------------------|---------|
| Unadjusted        | 4.4                                                   | 1.6–11.4                | 0.003   |
| Adjusted for hypertension, BMI | 4.2                                                   | 1.5–11.6                | 0.005   |
| Adjusted for stent diameter, type of stents, number of stents | 6.6                                                   | 1.9–23.0                | 0.003   |

BMI body mass index; SD standard deviation.

https://doi.org/10.1371/journal.pone.0232483.t003
that vaspin may play a role in the development of atherosclerosis also in slim or non-diabetic patients. However, still little is known for the association of vaspin with atherosclerosis.\cite{16,17}

Due to the fact that intima hyperplasia induced by smooth muscle cell migration plays a key role in the development of atherosclerosis\cite{18} as well as in the development of in-stent restenosis\cite{19} the effects of vaspin on smooth muscle cell migration and the occurrence of ISR in correlation to the baseline plasma levels of patients with stable coronary artery disease were of special interest in our study.

Fig 2. Correlation of late lumen loss with vaspin plasma levels before PCI; $R = 0.3$, $p < 0.05$.

https://doi.org/10.1371/journal.pone.0232483.g002
We were able to show for the first time that plasma levels of vaspin are able to predict the occurrence of ISR in patients with stable CAD, independently from established CV risk factors. In addition, we could show a correlation to the late lumen loss of the stented segment of the coronary artery with plasma vaspin levels before PCI. These findings are in line with our in-vitro data showing a dose dependent effect on smooth muscle cell migration.

Vaspin is thought to belong to the serpin family [9,10] but the molecular target and its mode of action is not fully understood. Heiker at al. were able to determine kallikrein 7 as a first target of vaspin which could be the physiological mechanism for its compensatory actions on obesity-induced insulin resistance [20]. The effects of vaspin on smooth muscle cell migration has already been studied in an rat animal model.[21] However, due to the fact of the well
described differences in gene expression patterns between different types of smooth muscle cells within one organism[22] we reinvestigated the described effect on smooth muscle cell migration in cells derived from human coronary arteries. We were able to reproduce the described inhibitory effect of vaspin on serum induced smooth muscle cell migration in a human *in vitro* model for the first time. A recent study in rat smooth muscle cells has shown that vaspin attenuates high glucose-induced proliferation and chemokinesis. In addition, it has been demonstrated that this effect was mediated by PI3K/Akt pathway as vaspin significantly attenuated Akt phosphorylation *in vitro* [23]. This in line with previous studies that demonstrated that the PI3K/Akt pathway is central in the development of intima hyperplasia after vascular injury *in vivo* [24][25]. Further we could show that vaspin has no effect on the migration and the proliferation of HUVEC. In contrast to the inhibitory effect of vaspin on the PI3K/Akt pathway in smooth muscle cell, vaspin has been shown to induce Akt activation in human aortic endothelial cells, protecting them thereby from free fatty acid-induced apoptosis [26]. This is of vital importance for the endothelialization of the stent after implantation which determines the long-term outcome and the risk for acute stent-thromosis and myocardial infarction. In combination with our clinical data, this gives us strong evidence for the observed

**Fig 4. Effect of vaspin on proliferation *in vitro*.** Human coronary smooth muscle cells and human umbilical vein endothelial cells were seeded at a concentration of 2000 cells/well in the wells of an electronic microtiter plate. After 24h differences in impedance, which represents proliferation, were measured.

https://doi.org/10.1371/journal.pone.0232483.g004
correlation between the development of in-stent restenosis and the pre-interventional plasma levels of vaspin in an individual patient. Further the observed strong inhibitory effect on HCASMC but not on HUVEC in vitro. The almost abolished serum induced cell migration of HCASMC could be an explanation for the fact that in patients with the highest plasma vaspin levels no in-stent restenosis occurred. Interestingly, it has been shown recently that vaspin has also direct effects on human macrophages and treatment with vaspin reduces an inflammatory phenotype of human macrophages by nuclear factor κB down-regulation and significantly suppresses oxidized low-density lipoprotein-induced foam cell formation. This was associated with significantly reduced intraplaque inflammation in an in vivo model that employed chronic infusion of vaspin into Apoe−/− mice (PMID 29891806).

The source of circulating vaspin in plasma is not fully understood. The highest tissue expression levels of vaspin were found in liver brain and skin compared to only modest expression in adipose tissue, spleen and low or non-detectable expression in bone marrow, muscle and kidney[27]. Interestingly, Sato et al was able to demonstrate that vaspin is expressed at high levels in atheromatous plaques in particular in foam cells in human coronary arteries. In contrast vaspin was not observed in human normal coronary arteries [28]. However, no data is available on the expression of vaspin in perivascular adipose tissue or vascular cells in vessels with intima hyperplasia.

Some limitations of the present study have to be acknowledged. As the primary endpoint of this study was angiographic restenosis, we included only patients that gave their informed consent for control angiography. However, we do not believe that selection bias plays a major role since these patients did not differ in respect to baseline characteristics and outcome from the total cohort of patients that had PCI with implantation of DES. Further, our study is necessarily of an observational nature. Accordingly, our results may be explained by unmeasured confounding factors. Therefore, we tried to control for baseline imbalances by multivariate modeling. The possibility of residual or undetected confounding is small but cannot be ruled out completely. In addition, in our study only first generation DES were analyzed, however biological mechanisms of ISR are similar between first and younger generations of DES. In addition, in our cohort ISR rates after implantation of Cypher or TAXUS stents were remarkable different. We therefore included stent type in the multivariate analysis and could demonstrate, that the association of vaspin plasma levels with ISR was independent of used stent.

In conclusion, determination of vaspin plasma levels before PCI might be helpful in the identification of patients with high risk for development of ISR after stent implantation. In addition, the selective effects of vaspin on smooth muscle cell migration could potentially be used to reduce ISR without inhibition of re-endothelialization of the stented segment.

Author Contributions

Conceptualization: Johann Wojta, Walter S. Speidl.
Data curation: Stefan P. Kastl, Katharina M. Katsaros, Konstantin A. Krychtiuk, Gerlinde Jägersberger, Christoph Kaun.
Formal analysis: Konstantin A. Krychtiuk, Christoph Kaun.
Funding acquisition: Kurt Huber, Johann Wojta, Walter S. Speidl.
Investigation: Katharina M. Katsaros.
Methodology: Kurt Huber, Johann Wojta, Walter S. Speidl.
Project administration: Stefan P. Kastl, Katharina M. Katsaros, Gerlinde Jägersberger, Johann Wojta, Walter S. Speidl.
Resources: Walter S. Speidl.
Supervision: Stefan P. Kastl, Kurt Huber, Johann Wojta, Walter S. Speidl.
Validation: Walter S. Speidl.
Writing – original draft: Stefan P. Kastl.
Writing – review & editing: Stefan P. Kastl, Walter S. Speidl.

References
1. Auer J, Leitner A, Berent R, Lamm G, Lassnig E, Krennmaier G. Long-term outcomes following coronary drug-eluting- and bare-metal-stent implantation. Atherosclerosis [Internet]. 2010/01/12. 2010; 210 (2):503–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2060973 doi: 10.1016/j.atherosclerosis.2009.12.003 PMID: 2060973
2. Habara M, Terashima M, Nasu K, Kandai H, Inoue K, Ito T, et al. Difference of tissue characteristics between early and very late restenosis lesions after bare-metal stent implantation: an optical coherence tomography study. Circ Cardiovasc Interv [Internet]. 2011 Jun [cited 2015 Nov 3]; 4(3):232–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21610225 doi: 10.1161/CIRCINTERVENTIONS.110.99999 PMID: 21610225
3. Park S-J, Kang S-J, Virmani R, Nakano M, Ueda Y. In-stent neatherosclerosis: a final common pathway of late stent failure. J Am Coll Cardiol [Internet]. 2012 Jun 5 [cited 2015 Nov 25]; 59(23):2051–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22651862 doi: 10.1016/j.jacc.2011.10.909 PMID: 22651862
4. Carter AJ, Laird JR, Farb A, Kufs W, Wortham DC, Virmani R. Morphologic characteristics of lesion formation and time course of smooth muscle cell proliferation in a porcine proliferative restenosis model. J Am Coll Cardiol [Internet]. 1994/11/01. 1994; 24(5):1398–405. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=7930266 doi: 10.1016/0735-1097(94)90126-0 PMID: 7930266
5. Rollins BJ. Chemokines. Blood [Internet]. 1997/08/01. 1997; 90(3):909–28. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9242519 PMID: 9242519
6. Furman MI, Benoit SE, Barnard MR, Valeri CR, Borbone ML, Becker RC, et al. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. J Am Coll Cardiol [Internet]. 1998/02/14. 1998; 31(2):352–8. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9462579 doi: 10.1016/s0735-1097(97)00510-x PMID: 9462579
7. Ott I, Neumann FJ, Gawaz M, Schmitt M, Schomig A. Increased neutrophil-platelet adhesion in patients with unstable angina. Circulation [Internet]. 1996/09/15. 1996; 94(6):1239–46. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8822975 doi: 10.1161/01.cir.94.6.1239 PMID: 8822975
8. Lago F, Diequez C, Gomez-Reino J, Guallilo O. The emerging role of adipokines as mediators of inflammation and immune responses. Cytokine Growth Factor Rev [Internet]. 2007/05/18. 2007; 18(3–4):313–25. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17507280 doi: 10.1016/j.cytogfr.2007.04.007 PMID: 17507280
9. Silverman GA, Bird PI, Carrell RW, Church FC, Coughlin PB, Gettins PG, et al. The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J Biol Chem [Internet]. 2001/07/21. 2001; 276(36):33293–6. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11435447 doi: 10.1074/jbc.R100016200 PMID: 11435447
10. Gettins PG. Serpin structure, mechanism, and function. Chem Rev [Internet]. 2002/12/12. 2002; 102(12):4751–804. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12475206 doi: 10.1021/cr010170+ PMID: 12475206
11. Hida K, Wada J, Eguchi J, Zhang H, Baba M, Seida A, et al. Visceral adipose tissue-derived serine proteinase inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci U S A [Internet]. 2005/07/21. 2005; 102(30):10616–5. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16030142 doi: 10.1073/pnas.0504703102 PMID: 16030142
12. Spiroglou SG, Kostopoulos CG, Varakis JN, Papadaki HH. Adipokines in periaortic and epicardial adipose tissue: differential expression and relation to atherosclerosis. J Atheroscler Thromb [Internet].
2010/02/11. 2010; 17(2):115–30. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=20145358 doi: 10.5551/jat.1735 PMID: 20145358

13. Wojta J, Gallicchio M, Zoellner H, Hufnagl P, Last K, Filonzi EL, et al. Thrombin stimulates expression of tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in cultured human vascular smooth muscle cells. Thromb Haemost [Internet]. 1993/09/01. 1993; 70(3):469–74. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8259551 PMID: 8259551

14. Demyanets S, Konya V, Kastl SP, Kauner C, Rauscher S, Niessner A, et al. Interleukin-13 induces Expression of Adhesion Molecules and Inflammatory Activation in Human Endothelial Cells and in Human Atherosclerotic Plaques. Arter Thromb Vasc Biol [Internet]. 2011 Sep [cited 2015 Nov 11]; 31(9):2080–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21737781

15. Esaki E, Adachi H, Hirai Y, Yamagishi S Ichi, Kakuma T, Enomoto M, et al. Serum vaspin levels are positively associated with carotid atherosclerosis in a general population. Atherosclerosis. 2014; 233(1):248–52. https://doi.org/10.1016/j.atherosclerosis.2013.12.040 PMID: 24529152

16. Jung CH, Lee WJ, Hwang JY, Lee MJ, Seol SM, Kim YM, et al. Vaspin increases nitric oxide bioavailability through the reduction of asymmetric dimethylarginine in vascular endothelial cells. PLoS One [Internet]. 2012 Jan [cited 2015 Nov 25]; 7(12):e52346. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3522088&tool=pmcentrez&rendertype=abstract doi: 10.1371/journal.pone.0052346 PMID: 23284999

17. Nakatsuka A, Wada J, Iseda I, Teshigawara S, Higashio K, Murakami K, et al. Visceral adipose tissue-derived serine proteinase inhibitor inhibits apoptosis of endothelial cells as a ligand for the cell-surface GRP78/voltage-dependent anion channel complex. Circ Res [Internet]. 2013 Mar 1 [cited 2015 Nov 25]; 112(5):771–80. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23307819 doi: 10.1161/CIRCRESAHA.111.300049 PMID: 23307819

18. Johnson JL. Emerging regulators of vascular smooth muscle cell function in the development and progression of atherosclerosis. Cardiovasc Res [Internet]. 2014 Sep 1 [cited 2015 Nov 25]; 103(4):452–60. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25053639 doi: 10.1093/cvr/cvu171 PMID: 25053639

19. Mitra AK, Agrawal DK. In stent restenosis: bane of the stent era. J Clin Pathol [Internet]. 2006 Mar [cited 2015 Nov 2]; 59(3):232–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16505271 doi: 10.1111/j.1365-2640.2005.02574.x

20. Heiker JT, Költén N, Kovacs P, Kuettern EB, Sträther N, Schultz S, et al. Vaspin inhibits kallikrein 7 by serpin mechanism. Cell Mol Life Sci. 2013 Jul; 70(14):2569–83. https://doi.org/10.1007/s00018-013-1258-8 PMID: 23370777

21. Phalitakul S, Okada M, Hara Y, Yamawaki H. A novel adipocytokine, vaspin inhibits platelet-derived growth factor-BB-induced migration of vascular smooth muscle cells. Biochem Biophys Res Commun. 2011 Sep 23; 413(2):264–9. https://doi.org/10.1016/j.bbrc.2011.08.083 PMID: 21893030

22. Adams LD, Geary RL, McManus B, Schwartz SM. A Comparison of Aorta and Vena Cava Medial Message Expression by cDNA Array Analysis Identifies a Set of 68 Consistently Differentially Expressed Genes, All of which are Tissue-type Plasminogen Activator and Plasminogen Activator Inhibitor Type 1 in Cultured Human Vascular Smooth Muscle Cells. Thromb Haemost [Internet]. 1993/09/01. 1993; 70(3):469–74. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8259551 PMID: 8259551

23. Smirnova NF, Gayral S, Pedros C, Loirand G, Vaillant N, Malet N, et al. Targeting PI3K prevents inflammatory response and restenosis after artery injury. Biosci Rep. 2017 Oct 31; 37(5). https://doi.org/10.1042/BSR20170089

24. Bilancio A, Rinaldi B, Oliviero MA, Donniacuo M, Monti MG, Boscaino A, et al. Inhibition of p110<sup>α</sup> PI3K prevents inflammatory response and restenosis after artery injury. Biosci Rep. 2017 Oct 31; 37(5).

25. Jung CH, Lee WJ, Hwang JY, Seol SM, Kim YM, Lee YL, et al. Vaspin protects vascular endothelial cells against free fatty acid-induced apoptosis through a phosphatidylinositol 3-kinase/Akt pathway. Biochem Biophys Res Commun. 2011 Sep 23; 413(2):264–9. https://doi.org/10.1016/j.bbrc.2011.08.083 PMID: 21893030

26. Weiner J, Zieger K, Pippel J, Heiker JT. Molecular Mechanisms of Vaspin Action—From Adipose Tissue to Skin and Bone, from Blood Vessels to the Brain. In: Advances in Experimental Medicine and Biology. Springer; 2019. p. 159–88.

27. Sato K, Shirai R, Yamaguchi M, Yamashita T, Shibata K, Okano T, et al. Anti-atherogenic effects of vaspin on human aortic smooth muscle cell/macrophage responses and hyperlipidemic mouse plaque phenotype. Int J Mol Sci. 2018 Jun 11; 19(6).